Catalent, Inc. (NYSE:CTLT – Get Rating) CEO Alessandro Maselli sold 816 shares of Catalent stock in a transaction dated Tuesday, July 26th. The shares were sold at an average price of $106.90, for a total value of $87,230.40. Following the sale, the chief executive officer now owns 25,083 shares of the company’s stock, valued at approximately $2,681,372.70. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Catalent Price Performance
Shares of Catalent stock opened at $113.10 on Friday. The company has a debt-to-equity ratio of 0.90, a current ratio of 2.89 and a quick ratio of 2.25. The business’s 50 day simple moving average is $106.25 and its two-hundred day simple moving average is $102.89. The stock has a market capitalization of $20.27 billion, a P/E ratio of 40.98, a price-to-earnings-growth ratio of 1.64 and a beta of 1.32. Catalent, Inc. has a one year low of $86.34 and a one year high of $142.64.
Catalent (NYSE:CTLT – Get Rating) last announced its quarterly earnings results on Tuesday, May 3rd. The company reported $1.00 EPS for the quarter, topping analysts’ consensus estimates of $0.89 by $0.11. The business had revenue of $1.27 billion for the quarter, compared to analysts’ expectations of $1.22 billion. Catalent had a return on equity of 15.07% and a net margin of 10.72%. The business’s quarterly revenue was up 20.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.78 EPS. Analysts forecast that Catalent, Inc. will post 3.57 EPS for the current year.
Hedge Funds Weigh In On Catalent
Wall Street Analyst Weigh In
Separately, Deutsche Bank Aktiengesellschaft dropped their target price on Catalent from $129.00 to $110.00 and set a “hold” rating for the company in a research report on Tuesday, April 12th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $142.86.
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services.
- Get a free copy of the StockNews.com research report on Catalent (CTLT)
- MarketBeat: Week in Review 7/25 – 7/29
- Procter’s Earnings Start To Show Weakness In Q4
- The One Question You Have to Ask Before Investing in INTC Stock
- Home Depot: A Beautiful Boring Stock to Navigate a Bear Market
- Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.